WuXi Biologics' issued shares increase from option exercises

For the month ended September 30, 2025, WuXi Biologics (Cayman) Inc. reported an increase in its total number of issued ordinary shares by 16,427,217, bringing the total to 4,087,867,673. This expansion resulted from the exercise of various Pre-IPO Share Options, with total funds raised during the month from these exercises amounting to $2,847,637.08. The company's authorized/registered share capital remained at 6,000,000,000 ordinary shares with a par value of $0.000008333333, totaling $50,000.

The movements specifically stemmed from six tranches of Pre-IPO Share Options, with grant dates ranging from January 2016 to May 2017, leading to the issuance of 16,427,217 new shares. No further share options can be granted under the Pre-IPO Share Option Scheme.

The company also disclosed the repurchase of 23,180,000 ordinary shares on July 8 and 9, 2025, which were not yet canceled as of September 30, 2025. Additionally, there are outstanding ordinary shares approved for issuance under the Restricted Share Award Scheme (63,687,130 shares) and the Share Award Scheme for Global Partner Program (9,233,053 shares).